-
1 Comment
Bukwang Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 13.5% below its 200 day moving average.
From a valuation standpoint, the stock is 0.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.5.
Bukwang Pharmaceutical Co., Ltd's total revenue sank by 3.7% to $49B since the same quarter in the previous year.
Its net income has dropped by 126.9% to $-2B since the same quarter in the previous year.
Finally, its free cash flow grew by 104.7% to $404M since the same quarter in the previous year.
Based on the above factors, Bukwang Pharmaceutical Co., Ltd gets an overall score of 2/5.
Exchange | KO |
---|---|
CurrencyCode | KRW |
ISIN | KR7003000007 |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Beta | 0.95 |
---|---|
Market Cap | 274B |
PE Ratio | None |
Target Price | 29167 |
Dividend Yield | None |
Bukwang Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products in South Korea and internationally. It offers its products in oral solid dosage forms, injections, oral solutions, external solutions, and ointments. The company also provides ethical drugs, including drugs for treating diabetic peripheral neuropathy, hypothyroidism, toxic liver disease, chronic hepatitis, liver cirrhosis, and iron-deficiency anemia; over-the-counter drugs, such as fever and pain relief medication, gastrointestinal medication, cold medication, laxatives for constipation, collagen supplements, multivitamin supplements, mouthwash, topical gels, oral health supplements, and omega-3 supplements; and personal products comprising toothpastes, toothbrushes, and other oral care products; nutraceuticals; health functional foods; and quasi drugs. In addition, it offers products for various threptic areas, including endocrinology, gastroenterology, cardiology, oncology, central nervous system, iron supplements, neuropsychiatry, respiratory/allergy, dermatology, urology, and other treatment areas. Further, the company's development pipeline comprises Lurasidone for the treatment of schizophrenia and bipolar depression; JM-010, for treating dyskinesia in parkinson's disease; SOL-804, which is used for the treatment of metastatic castration resistant prostate cancer; AhR Inhibitor for solid tumors; PKR Inhibitor for neurodegenerative disorders; and PD Program for parkinson's disease. Bukwang Pharmaceutical Co., Ltd. was founded in 1960 and is headquartered in Seoul, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 003000.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025